Novo’s semaglutide hits secondary endpoints in Ph3 kidney disease trial, cutting risks of cardio events and death - Endpoints News
endpts.comSubmitted by endpointsnews6292 in news
Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the company's case for expanding the drug in a broad range of…